Search the Newsreel

Burning Rock Biotech (BNR) Climbs 4.05% to $9.24 as Precision Oncology Names Attract Fresh Buying - Analyst Upgrade Stocks

Puma Biotechnology (PBYI) Earnings Date and Reports 2026

Zhengye’s closing bid price met Nasdaq’s $1 floor for 10 business days

Rossari Biotech withdraws from Nirmal Bang investor meet on Aug 10

$Zhengye Biotechnology (ZYBT.US)$ Will there be another miracle?[Grin][Cool Guy]

The article poses a question about whether Zhengye Biotechnology (ZYBT.US) will experience another "miracle." It's a brief post from a user named "活的踏实 活的精彩" within the moomoo Community, indicating a discussion about the stock's future performance. The post itself is minimal, serving primarily as …

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology, Inc. (VIR) reported Q2 earnings of $0.47 per share, significantly missing the Zacks Consensus Estimate of $0.83, though it represents an improvement from a loss of $0.8 per share a year ago. The company also missed revenue estimates, posting $238.95 million against …

Earnings call transcript: Vir Biotechnology jumps on q2 2026 cash and data gains

Vir Biotechnology reported strong Q2 2026 results, with net income of $80.1 million and cash reserves exceeding $1 billion, largely due to a collaboration payment from Astellas. The company's stock jumped over 10% after hours as investors reacted positively to the improved financial standing, …

Zhengye Biotechnology Company Profile & Introduction

This document appears to be a company profile and introduction for Zhengye Biotechnology. Without further content, a detailed summary is not possible, but it likely outlines the company's operations, mission, and key offerings within the biotechnology sector.

Vir Biotechnology (VIR) Releases Q2 2026 Earnings: Revenue and EPS Beat Estimates

Vir Biotechnology (VIR) reported strong Q2 2026 earnings, exceeding Wall Street estimates with $238.9 million in revenue and $0.47 diluted EPS. The company also demonstrated robust cash generation and ended the quarter with substantial cash and cash equivalents. Insider trading data shows significant sales …

Vir Biotechnology Inc. (VIR) Tops Q2 EPS by 14c

Vir Biotechnology Inc. (VIR) surpassed analyst expectations for its second-quarter earnings, reporting an EPS of $0.47, which was $0.14 higher than the estimated $0.33. The company also significantly beat revenue forecasts, achieving $238.94 million against a consensus estimate of $135.88 million.

Vir Biotechnology (NASDAQ: VIR) swings to profit on $239.3M Astellas deal

Vir Biotechnology reported a substantial swing to profit in Q2 2026, driven by a $239.3 million licensing and collaboration revenue from its VIR-5500 deal with Astellas. The company posted a net income of $80,080 thousand, a significant improvement from a net loss of $110,958 …

Vir Biotechnology posts $238.9M Q2 revenue, $80.1M net income; $1.01B cash runway into H2 2028

Moleculin Biotech (MBRX) CSO buys common stock and Series I Warrants

Moleculin Biotech's Chief Science Officer, Donald H. Picker, recently purchased 173,333 shares of common stock and Series I Warrants to acquire an additional 519,999 shares. These transactions occurred on August 3, 2026, as part of a public offering at a combined price of $0.75 …

Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today

Krystal Biotech (KRYS) After Its Q2 Beat Is The Valuation Case Still Intact

Krystal Biotech (KRYS) reported strong Q2 2026 results, exceeding analyst expectations with robust Vyjuvek sales and expanding market reach. Despite a recent short-term share price dip, longer-term performance remains strong. The article discusses two valuation perspectives: one suggesting the stock is 10.2% undervalued based …

Evaxion Biotech A/S (EVAX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Evaxion Biotech A/S (EVAX) has an earnings forecast score of 8.00, ranking 171st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $11.00 for EVAX, with a high of $16.00 and a low of $10.00. Most analysts recommend …

Edesa Biotech Inc (EDSA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Edesa Biotech Inc (EDSA) has an earnings forecast score of 8.00, ranking 169th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $9.00, with a high of $19.00 and a low of $5.00, and predominantly recommend a "Buy" …

Shandong Boan Files for Brazil Approval of EYLEA Biosimilar BA9101

Investors brace for Vir Biotech earnings amid turnaround bid By Investing.com

Vir Biotechnology Inc. is preparing to report second-quarter earnings, with analysts expecting a significant turnaround after a challenging first quarter. The company faces scrutiny regarding its revenue forecast, the progress of its hepatitis B pipeline, and a recent CFO transition. Investors are looking for …

Price to sales forward of Moleculin Biotech, Inc. – LS:A41SET

This article provides financial information for Moleculin Biotech, Inc. (A41SET) on the TradingView platform. It specifically highlights the "Price to sales forward" metric for the company, accessible through the Lang & Schwarz Tradecenter. The content itself is minimalist, primarily serving as a header for …

Stock Radar: Concord Biotech stock showing signs of rebound after falling over 20% from highs; time to buy

Krystal Biotech, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:KRYS) 2026-08-05

Krystal Biotech (KRYS) reported its Q2 2026 earnings, missing both EPS and revenue estimates. Despite the miss, the company highlighted 24% revenue growth for its product VYJUVEK and anticipates several pipeline readouts over the next 12 to 18 months, signaling a potential shift towards …

Global Market: European shares climb as earnings, US-Iran diplomacy lift sentiment

Vir Biotechnology (VIR) Earnings Date and Reports 2026 $VIR

Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Kelun-Biotech Sets August Board Meeting and Global Webcast for 2026 Interim Results

Adaptive Biotechnologies (ADPT) Stock Gains Little As MRD Growth Meets Wider Losses

Windlas Biotech schedules Q1FY27 earnings call for Aug 11

ADAPTIVE BIOTECHNOLOGIES CORP : PIPER SANDLER RAISES TARGET PRICE TO $27.50 FROM $20.00

Piper Sandler has increased its target price for Adaptive Biotechnologies Corp to $27.50 from $20.00. This adjustment reflects an updated outlook from the analyst firm regarding the company's valuation. The information was reported by Reuters.

Adaptive Biotechnologies (NASDAQ: ADPT) raises $345M in 2031 notes

Adaptive Biotechnologies (ADPT) has issued $345 million in 0% convertible senior notes due 2031, using part of the proceeds to repurchase revenue interests and common stock. The company reported a Q2 2026 revenue of $71.6 million, an increase from the previous year, driven by …

Edesa Biotech (NASDAQ: EDSA) CEO receives 5,324 restricted share units

Edesa Biotech's CEO, Pardeep Nijhawan, was granted 5,324 restricted share units on August 3, 2026, which vested immediately under the company's 2019 Equity Incentive Compensation Plan. Following this grant, Nijhawan directly holds 893,386 common shares, in addition to significant indirect holdings through various affiliated …

Adaptive Biotechnologies Corp Q2 2026: Revenue $71.6M, EPS $(0.25) — 10-Q Summary

Adaptive Biotechnologies Corp (ADPT) reported Q2 2026 financial results, with revenue reaching $71.6 million, an increase from $58.9 million in the previous year. The company recorded a net loss of $(39.8) million and a diluted loss per share of $(0.25). Key drivers included a …

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

Puma Biotechnology, Inc. will host a conference call on Thursday, February 26, 2026, at 1:30 p.m. PT/4:30 p.m. ET to discuss its fourth quarter and full year 2025 financial results. The call details and webcast information are provided for investors and interested parties. The …

Moleculin Biotech (NasdaqCM:MBRX) Stock Forecast & Analyst Predictions

Moleculin Biotech (MBRX) is forecast to increase earnings by 54.7% and revenue by 74.8% annually, with EPS expected to grow by 75.4%. The company's lead drug candidate, Annamycin, is progressing through pivotal Phase 2/3 MIRACLE trials for relapsed or refractory acute myeloid leukemia (R/R …

The Manufacturers Life Insurance Company Cuts Stake in Krystal Biotech, Inc. $KRYS

The Manufacturers Life Insurance Company reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.2% in the first quarter, selling 4,560 shares and retaining 36,069 shares valued at approximately $9.3 million. Despite beating EPS estimates, Krystal Biotech's revenue fell short of analyst forecasts, though …

KRYSTAL BIOTECH INC : BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $392 FROM $396

BofA Global Research has lowered its price objective for Krystal Biotech Inc. (KRYS.O) from $396 to $392. This adjustment reflects a revised outlook from the research firm regarding the biotechnology company. The article provides this key financial update from Reuters.